Gemcitabine
- Generic Name
- Gemcitabine
- Brand Names
- Gemzar
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11F2N3O4
- CAS Number
- 95058-81-4
- Unique Ingredient Identifier
- B76N6SBZ8R
- Background
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...
- Indication
Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.
In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...
- Associated Conditions
- Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
- Associated Therapies
- -
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00151034
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
🇺🇸California City of Hope National Medical Group, Duarte, California, United States
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- Aktion Bronchialkarzinom e.V.
- Target Recruit Count
- 280
- Registration Number
- NCT00148395
- Locations
- 🇩🇪
Klinikum Kassel GmbH, Kassel, Germany
Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2009-09-07
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 60
- Registration Number
- NCT00147875
- Locations
- 🇩🇪
University of Cologne, Cologne, NRW, Germany
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2006-09-27
- Lead Sponsor
- Association of Urologic Oncology (AUO)
- Target Recruit Count
- 178
- Registration Number
- NCT00146276
- Locations
- 🇩🇪
Saarland University, Homburg/Saar, Saarland, Germany
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2008-01-10
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT00148135
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT00142467
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT00142571
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder
- Conditions
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 68
- Registration Number
- NCT00136175
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas
- Conditions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00134641
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 46
- Registration Number
- NCT00128856
- Locations
- 🇪🇸
Hospital Universitario La Princesa, Madrid, Spain
🇪🇸Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.